Skip to main content
SpringerLink
Log in

First-Line Chemotherapy for Malignant Pleural Mesothelioma

  • Chapter
Malignant Mesothelioma

  • 934 Accesses

Summary

Most patients with malignant mesothelioma are candidates for systemic chemotherapy during the course of their disease, but no standard regimen has been established. Several phase II single-agent and combination chemotherapy studies have been performed over the past two decades. Although the true impact of chemotherapy in mesothelioma remains to be determined, agents with consistent antitumor activity include the platinum agents and the antifolates. Phase II studies of combination chemotherapy are associated with higher response rates but not necessarily longer median survivals. Recent data from a large randomized phase III clinical trial established the superiority of cisplatin/pemetrexed compared to cisplatin alone. Data from this and other ongoing studies will help establish standard chemotherapy regimens for mesothelioma and provide a basis for combination studies with molecular agents and incorporation of these regimens into multimodality treatment approaches.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Ruffie P, Feld R, Minkin S, et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol 1989;7:1157–1168.

    PubMed  CAS  Google Scholar 

  2. Herndon JE, Green MR, Chahinian AP, et al. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest 1998;113:723–731.

    PubMed  CAS  Google Scholar 

  3. Girling DJ, Muers MF, Qian W, et al. Multicenter randomized controlled trial of the management of unresectable malignant mesothelioma proposed by the British Thoracic Society and the British Medical Research Council. Semin Oncol 2002;29:97–101.

    Article  PubMed  Google Scholar 

  4. Steele JP, Shamash J, Evans MT, et al. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 2000;18:3912–3917.

    PubMed  CAS  Google Scholar 

  5. Middleton GW, Smith IE, O’Brien ME, et al. Good symptom relief with palliative MVP (mitomycin-C, vinblastine and cisplatin) chemotherapy in malignant mesothelioma. Ann Oncol 1998;9:269–273.

    Article  PubMed  CAS  Google Scholar 

  6. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365–376

    PubMed  CAS  Google Scholar 

  7. Muers MF, Rudd R, Hodson A, et al. A feasibility study of active symptom control (ASC) with or without chemotherapy in malignant pleural mesothelioma. In: Hansen HH, ed. 10th World Conference on Lung Cancer. Vancouver, Canada: International Association for the Study of Lung Cancer, 2003:S11.

    Google Scholar 

  8. Nowak AK, Byrne MJ, Williamson R, et al. A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 2002;87:491–496.

    Article  PubMed  CAS  Google Scholar 

  9. Hollen PJ, Gralla RJ, Liepa AM, et al. Validation of a quality of life instrument in patients with pleural mesothelioma: Lung Cancer Symptom Scale (LCSS). In: Grunberg SM, ed. American Society of Clinical Oncology. San Francisco: American Society of Clinical Oncology, 2001.

    Google Scholar 

  10. Gralla RJ, Hollen PJ, Liepa AM, et al. Improving quality of life in patients with malignant pleural mesothelioma: results of the randomized pemetrexed + cisplatin vs. cisplatin trial using LCSS-meso instrument. In: Grunberg SM, ed. American Society of Clinical Oncology. Chicago: American Society of Clinical Oncology, 2003.

    Google Scholar 

  11. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636–2644.

    Article  PubMed  CAS  Google Scholar 

  12. Vogelzang NJ, Rusthoven J, Paoletti P, et al. Phase III single-blinded study of pemetrexed + cisplatin vs. cisplatin alone in chemonaive patients with malignant pleural mesothelioma. Proc Am Soc Clin Oncol 2002;21:abstract 5.

    Google Scholar 

  13. Paoletti P, Pistolesi M, Rusthoven JJ, et al. Correlation of pulmonary function tests with best tumor response status: results from the phase III study of pemetrexed + cisplatin vs. cisplatin in malignant pleural mesothelioma. In: Grunberg SM, ed. American Society of Clinical Oncology. Chicago: American Society of Clinical Oncology, 2003.

    Google Scholar 

  14. Maksymiuk AW, Marschke RF Jr, Tazelaar HD, et al. Phase II trial of topotecan for the treatment of mesothelioma. Am J Clin Oncol 1998;21:610–613.

    Article  PubMed  CAS  Google Scholar 

  15. Kindler HL, Herndon JE, Vogelzang NJ, et al. CPT-11 in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (CALGB 9733). In: Perry MC, ed. American Society of Clinical Oncology. New Orleans: American Society of Clinical Oncology, 2000.

    Google Scholar 

  16. Martensson G, Sorenson S. A phase II study of vincristine in malignant mesothelioma—a negative report. Cancer Chemother Pharmacol 1989;24:133–134.

    PubMed  CAS  Google Scholar 

  17. Cowan JD, Green S, Lucas J, et al. Phase II trial of five day intravenous infusion vinblastine sulfate in patients with diffuse malignant mesothelioma: a Southwest Oncology Group study. Invest New Drugs 1998;6:247–248.

    Google Scholar 

  18. van Meerbeeck J, Debruyne C, van Zandwijk N, et al. Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group. Br J Cancer 1996;74:961–963.

    PubMed  Google Scholar 

  19. Lerner HJ, Schoenfeld DA, Martin A, et al. Malignant mesothelioma. The Eastern Cooperative Oncology Group (ECOG) experience. Cancer 1983;52:1981–1985.

    Article  PubMed  CAS  Google Scholar 

  20. Sorensen PG, Bach F, Bork E, et al. Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma. Cancer Treat Rep 1985;69:1431–1432.

    PubMed  CAS  Google Scholar 

  21. Vogelzang N, Taub R, Shin D, et al. Phase III randomized trial of onconase (onc) vs. doxorubicin (dox) in patients (pts) with unresectable malignant mesothelioma (umm): analysis of survival. In: Perry MC, ed. American Society of Clinical Oncology. New Orleans: American Society of Clinical Oncology, 2000:577a.

    Google Scholar 

  22. Berghmans T, Paesmans M, Lalami Y, et al. Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis. Lung Cancer 2002;38:111–121.

    Article  PubMed  CAS  Google Scholar 

  23. Bueno R, Appasani K, Mercer H, et al. The alpha folate receptor is highly activated in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 2001;121:225–233.

    Article  PubMed  CAS  Google Scholar 

  24. Khokhar NZ, Lam AF, Rusch VW, et al. Despite some expression of folate receptor alpha in human mesothelioma cells, internalization of methotrexate is predominantly carrier mediated. J Thorac Cardiovasc Surg 2002;123:862–868.

    Article  PubMed  CAS  Google Scholar 

  25. Wang Y, Zhao R, Chattopadhyay S, et al. A novel folate transport activity in human mesothelioma cell lines with high affinity and specificity for the new-generation antifolate, pemetrexed. Cancer Res 2002;62:6434–6437.

    PubMed  CAS  Google Scholar 

  26. Illei PB, Rusch VW, Zakowski MF, et al. Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. Clin Cancer Res 2003;9:2108–2013.

    PubMed  CAS  Google Scholar 

  27. Chen ZH, Olopade OI, Savarese TM. Expression of methylthioadenosine phosphorylase cDNA in p16-, MTAP-malignant cells: restoration of methylthioadenosine phosphorylase-dependent salvage pathways and alterations of sensitivity to inhibitors of purine de novo synthesis. Mol Pharmacol 1997;52:903–911.

    PubMed  CAS  Google Scholar 

  28. Hori H, Tran P, Carrera CJ, et al. Methylthioadenosine phosphorylase cDNA transfection alters sensitivity to depletion of purine and methionine in A549 lung cancer cells. Cancer Res 1996;56:5653–5658.

    PubMed  CAS  Google Scholar 

  29. Byrne MJ, Davidson JA, Musk AW, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 1999;17:25–30.

    PubMed  CAS  Google Scholar 

  30. van Haarst JM, Baas P, Manegold C, et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 2002;86:342–345.

    Article  PubMed  Google Scholar 

  31. Favaretto AG, Aversa SM, Paccagnella A, et al. Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multi-centric phase II study. Cancer 2003;97:2791–2797.

    Article  PubMed  CAS  Google Scholar 

  32. van Breukelen FJ, Mattson K, Giaccone G, et al. Mitoxantrone in malignant pleural mesothelioma: a study by the EORTC Lung Cancer Cooperative Group. Eur J Cancer 1991;27:1627–1629.

    Article  PubMed  Google Scholar 

  33. Eisenhauer EA, Evans WK, Raghavan D, et al. Phase II study of mitoxantrone in patients with mesothelioma: a National Cancer Institute of Canada Clinical Trials Group Study. Cancer Treat Rep 1986;70:1029–1030.

    PubMed  CAS  Google Scholar 

  34. Mattson K, Giaccone G, Kirkpatrick A, et al. Epirubicin in malignant mesothelioma: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1992;10:824–828.

    PubMed  CAS  Google Scholar 

  35. Magri MD, Veronesi A, Foladore S, et al. Epirubicin in the treatment of malignant mesothelioma: a phase II cooperative study. The North-Eastern Italian Oncology Group (GOCCNE)-Mesothelioma Committee. Tumori 1991;77:49–51.

    PubMed  CAS  Google Scholar 

  36. Kaukel E, Koschel G, Gatzemeyer U, et al. A phase II study of pirarubicin in malignant pleural mesothelioma. Cancer 1990;66:651–654.

    Article  PubMed  CAS  Google Scholar 

  37. Colbert N, Vannetzel JM, Izrael V, et al. A prospective study of detorubicin in malignant mesothelioma. Cancer 1985;56:2170–2174.

    Article  PubMed  CAS  Google Scholar 

  38. Hudis CA, Kelsen DP. Menogaril in the treatment of malignant mesothelioma: a phase II study. Invest New Drugs 1992;10:103–106.

    Article  PubMed  CAS  Google Scholar 

  39. Baas P, van Meerbeeck J, Groen H, et al. Caelyx in malignant mesothelioma: a phase II EORTC study. Ann Oncol 2000;11:697–700.

    Article  PubMed  CAS  Google Scholar 

  40. Oh Y, Perez-Soler R, Fossella FV, et al. Phase II study of intravenous Doxil in malignant pleural mesothelioma. Invest New Drugs 2000;18:243–245.

    Article  PubMed  CAS  Google Scholar 

  41. Steele JP, O’Doherty CA, Shamash J, et al. Phase II trial of liposomal daunorubicin in malignant pleural mesothelioma. Ann Oncol 2001;12:497–499.

    Article  PubMed  CAS  Google Scholar 

  42. Mintzer DM, Kelsen D, Frimmer D, et al. Phase II trial of high-dose cisplatin in patients with malignant mesothelioma. Cancer Treat Rep 1985;69:711–712.

    PubMed  CAS  Google Scholar 

  43. Zidar BL, Green S, Pierce HI, et al. A phase II evaluation of cisplatin in unresectable diffuse malignant mesothelioma: a Southwest Oncology Group Study. Invest New Drugs 1988;6:223–226.

    Article  PubMed  CAS  Google Scholar 

  44. Raghavan D, Gianoutsos P, Bishop J, et al. Phase II trial of carboplatin in the management of malignant mesothelioma. J Clin Oncol 1990;8:151–154.

    PubMed  CAS  Google Scholar 

  45. Vogelzang NJ, Goutsou M, Corson JM, et al. Carboplatin in malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B. Cancer Chemother Pharmacol 1990;27:239–242.

    Article  PubMed  CAS  Google Scholar 

  46. Solheim OP, Saeter G, Finnanger AM, et al. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura. A phase II study. Br J Cancer 1992;65:956–960.

    PubMed  CAS  Google Scholar 

  47. Vogelzang NJ, Weissman LB, Herndon JE II, et al. Trimetrexate in malignant mesothelioma: a Cancer and Leukemia Group B Phase II study. J Clin Oncol 1994;12:1436–1442.

    PubMed  CAS  Google Scholar 

  48. Kindler HL, Belani CP, Herndon JE II, et al. Edatrexate (10-ethyldeaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B. Cancer 1999;86:1985–1991.

    Article  PubMed  CAS  Google Scholar 

  49. Cantwell BM, Earnshaw M, Harris AL. Phase II study of a novel antifolate, N10-propargyl-5,8 dideazafolic acid (CB3717), in malignant mesothelioma. Cancer Treat Rep 1986;70:1335–1336.

    PubMed  CAS  Google Scholar 

  50. Harvey VJ, Slevin ML, Ponder BA, et al. Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycin. Cancer 1984;54:961–964.

    Article  PubMed  CAS  Google Scholar 

  51. Vogelzang NJ, Herndon JE II, Cirrincione C, et al. Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B. Cancer 1997;79:2237–2242.

    Article  CAS  Google Scholar 

  52. Baas P, Ardizzoni A, Grossi F, et al. The activity of raltitrexed (Tomudex) in malignant pleural mesothelioma: an EORTC phase II study (08992). Eur J Cancer 2003;39:353–357.

    Article  PubMed  CAS  Google Scholar 

  53. Scagliotti GV, Shin DM, Kindler HL, et al. Phase II Study of Pemetrexed With and Without Folic Acid and Vitamin B12 as Front-line Therapy in Malignant Pleural Mesothelioma. J Clin Oncol 2003;21:1556–1561.

    Article  PubMed  CAS  Google Scholar 

  54. Kindler HL, Millard F, Herndon JE II, et al. Gemcitabine for malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B. Lung Cancer 2001;31:311–317.

    Article  PubMed  CAS  Google Scholar 

  55. van Meerbeeck JP, Baas P, Debruyne C, et al. A Phase II study of gemcitabine in patients with malignant pleural mesothelioma. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. Cancer 1999;85:2577–2582.

    Article  PubMed  Google Scholar 

  56. Bischoff HG, Manegold C, Knopp M, et al. Gemcitabine (Gemzar) may reduce tumor load and tumor associated symptoms in malignant pleural mesothelioma. In: Perry MC, ed. American Society of Clinical Oncology. Los Angeles, CA, American Society of Clinical Oncology, 1998.

    Google Scholar 

  57. Dirix LY, van Meerbeeck J, Schrijvers D, et al. A phase II trial of dose-escalated doxorubicin and ifosfamide/mesna in patients with malignant mesothelioma. Ann Oncol 1994;5:653–655.

    PubMed  CAS  Google Scholar 

  58. Carmichael J, Cantwell BM, Harris AL. Aphase II trial of ifosfamide/mesna with doxorubicin for malignant mesothelioma. Eur J Cancer Clin Oncol 1989;25:911–912.

    Article  PubMed  CAS  Google Scholar 

  59. Shin DM, Fossella FV, Umsawasdi T, et al. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma. Cancer 1995;76:2230–2236.

    Article  PubMed  CAS  Google Scholar 

  60. Chahinian AP, Pajak TF, Holland JF, et al. Diffuse malignant mesothelioma. Prospective evaluation of 69 patients. Ann Intern Med 1982;96:746–755.

    PubMed  CAS  Google Scholar 

  61. Pennucci MC, Ardizzoni A, Pronzato P, et al. Combined cisplatin, doxorubicin, and mitomycin for the treatment of advanced pleural mesothelioma: a phase II FONICAP trial. Italian Lung Cancer Task Force. Cancer 1997;79:1897–1902.

    Article  PubMed  CAS  Google Scholar 

  62. Samson MK, Wasser LP, Borden EC, et al. Randomized comparison of cyclophosphamide, imidazole carboxamide, and adriamycin versus cyclophosphamide and adriamycin in patients with advanced stage malignant mesothelioma: a Sarcoma Intergroup Study. J Clin Oncol 1987;5:86–91.

    PubMed  CAS  Google Scholar 

  63. Upham JW, Musk AW, van Hazel G, et al. Interferon alpha and doxorubicin in malignant mesothelioma: a phase II study. Aust N Z J Med 1993;23:683–687.

    PubMed  CAS  Google Scholar 

  64. Samuels BL, Herndon JE 2nd, Harmon DC, et al. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Cancer 1998;82:1578–1584.

    Article  PubMed  CAS  Google Scholar 

  65. Nakano T, Chahinian AP, Shinjo M, et al. Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma: a pilot phase II clinical trial and pharmacokinetic profile. Cancer 1999;85:2375–2384.

    Article  PubMed  CAS  Google Scholar 

  66. Tsavaris N, Mylonakis N, Karvounis N, et al. Combination chemotherapy with cisplatin-vinblastine in malignant mesothelioma. Lung Cancer 1994;11:299–303.

    Article  PubMed  CAS  Google Scholar 

  67. Chahinian AP, Antman K, Goutsou M, et al. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol 1993;11:1559–1565.

    PubMed  CAS  Google Scholar 

  68. Ardizzoni A, Rosso R, Salvati F, et al. Activity of doxorubicin and cisplatin combination chemotherapy in patients with diffuse malignant pleural mesothelioma. An Italian Lung Cancer Task Force (FONICAP) Phase II study. Cancer 1991;67:2984–2987.

    Article  PubMed  CAS  Google Scholar 

  69. Parra HS, Tixi L, Latteri F, et al. Combined regimen of cisplatin, doxorubicin, and alpha-2b interferon in the treatment of advanced malignant pleural mesothelioma: a Phase II multicenter trial of the Italian Group on Rare Tumors (GITR) and the Italian Lung Cancer Task Force (FONICAP). Cancer 2001;92:650–656.

    Article  PubMed  CAS  Google Scholar 

  70. Eisenhauer EA, Evans WK, Murray N, et al. A phase II study of VP-16 and cisplatin in patients with unresectable malignant mesothelioma, An NCI Canada Clinical Trials Group Study. Invest New Drugs 1988;6:327–329.

    Article  PubMed  CAS  Google Scholar 

  71. Tansan S, Emri S, Selcuk T, et al. Treatment of malignant pleural mesothelioma with cisplatin, mitomycin C and alpha interferon. Oncology 1994;51:348–351.

    Article  PubMed  CAS  Google Scholar 

  72. Metintas M, Ozdemir N, Ucgun I, et al. Cisplatin, mitomycin, and interferon-alpha2a combination chemoimmunotherapy in the treatment of diffuse malignant pleural mesothelioma. Chest 1999;116:391–398.

    Article  PubMed  CAS  Google Scholar 

  73. Soulie P, Ruffie P, Trandafir L, et al. Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2a. J Clin Oncol 1996;14:878–885.

    PubMed  CAS  Google Scholar 

  74. Trandafir L, Ruffie P, Borel C, et al. Higher doses of alpha-interferon do not increase the activity of the weekly cisplatin-interferon combination in advanced malignant mesothelioma. Eur J Cancer 1997;33:1900–1902.

    Article  PubMed  CAS  Google Scholar 

  75. Kasseyet S, Astoul P, Boutin C. Results of a phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura. Cancer 1999;85:1740–1749.

    Article  PubMed  CAS  Google Scholar 

  76. Fizazi K, Caliandro R, Soulie P, et al. Combination raltitrexed (Tomudex(R))-oxaliplatin: a step forward in the struggle against mesothelioma? The Institute Gustave Roussy experience with chemotherapy and chemoimmunotherapy in mesothelioma. Eur J Cancer 2000;36:1514–1521.

    Article  PubMed  CAS  Google Scholar 

  77. O’Reilly EM, Ilson DH, Saltz LB, et al. A phase II trial of interferon alpha-2a and carboplatin in patients with advanced malignant mesothelioma. Cancer Invest 1999;17:195–200.

    Article  PubMed  CAS  Google Scholar 

  78. Hughes A, Calvert P, Azzabi A, et al. Phase I clinical and pharmacokinetic study of pemetrexed and carboplatin in patients with malignant pleural mesothelioma. J Clin Oncol 2002;20:3533–3544.

    Article  PubMed  CAS  Google Scholar 

  79. Fizazi K, Doubre H, Le Chevalier T, et al. Combination of raltitrexed and oxaliplatin is an active regimen in malignant mesothelioma: results of a phase II study. J Clin Oncol 2003;21:349–354.

    Article  PubMed  CAS  Google Scholar 

  80. Steele JP, Shamash J, Evans MT, et al. Phase II trial of vinorelbine and oxaliplatin (“VO”) in malignant pleural mesothelioma (MPM). In: Grunberg SM, ed. American Society of Clinical Oncology. San Francisco, California, American Society of Clinical Oncology, 2001:335a.

    Google Scholar 

  81. Schuette W, Blankenburg T, Lauerwald K, et al. A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma. Clinical Lung Cancer 2003;4:294–297.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

    Pasi A. Jänne MD, PhD

Authors
  1. Pasi A. Jänne MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Thoracic Oncology, Barbara Ann Karmanos Cancer Institute, Harper University Hospital, USA

    Harvey I. Pass MD (Chief and Professor of Surgery and Oncology) (Chief and Professor of Surgery and Oncology)

  2. Wayne State University School of Medicine, Detroit, MI, 48201, USA

    Harvey I. Pass MD (Chief and Professor of Surgery and Oncology) (Chief and Professor of Surgery and Oncology)

  3. Nevada Cancer Institute, USA

    Nicholas J. Vogelzang MD (Director and Clinical Professor) (Director and Clinical Professor)

  4. Department of Internal Medicine, University of Nevada School of Medicine, Las Vegas, NV, 81935, USA

    Nicholas J. Vogelzang MD (Director and Clinical Professor) (Director and Clinical Professor)

  5. Thoracic Oncology, Cardinal Bernardin Cancer Center, Loyola University Chicago, Stritch School of Medicine, Maywood, IL, 60153, USA

    Michele Carbone MD, PhD (Professor of Pathology, Director) (Professor of Pathology, Director)

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer Science+Business Media, Inc.

About this chapter

Cite this chapter

Jänne, P.A. (2005). First-Line Chemotherapy for Malignant Pleural Mesothelioma. In: Pass, H.I., Vogelzang, N.J., Carbone, M. (eds) Malignant Mesothelioma. Springer, New York, NY. https://doi.org/10.1007/0-387-28274-2_39

Download citation

  • DOI: https://doi.org/10.1007/0-387-28274-2_39

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-0-387-22949-2

  • Online ISBN: 978-0-387-28274-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation